Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 31 Aug 2025
Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.
714not yet publishedAug 25Sep 25Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26

Scope · likely financings by canton

50 likely financings · 2 Aug 2025 – 31 Aug 2025 · the feed below shows one weekBS ✕ show all cantonsMap: Natural Earth

Likely financing
Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided
Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased
No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round
A financing announcement on startupticker.ch names the company and matches this increase.

Published 25–31 Aug 2025 · canton BS

5 capital increases · 2 shown
Showing: likely financings and confirmed rounds ▾
Show
Capital increases published 25–31 Aug 2025
CompanyStatusNominal share capital (CHF)
before → after
New shares, % of
post-step shares
Announced roundnot disclosed in the SHABSHAB publishedSource
Windward Bio Group AGBS · Zweck der Gesellschaft ist der Erwerb, das Halten, die Verwaltung, die Verwertung und die Veräusserung von …SHAB publication HR02-1006419127Likely financingscore 0.60447’049.44 → 456’357.44New shares 2.0%2.0%—28 Aug 2025SHAB publication HR02-1006419127
Torpedo Pharmaceuticals AGBS · Die Gesellschaft bezweckt die Erforschung, die Entwicklung, die Herstellung, die Verwertung, den Erwerb, den …SHAB publication HR02-1006416952Likely financingscore 0.65102’575.54 → 105’278.25New shares 2.6%2.6%—26 Aug 2025SHAB publication HR02-1006416952

3 other capital increases published this week ▸